QR-Bromocriptine as an Adjunct to Insulin and Metformin in the Treatment of Type 2 Diabetes
Primary Purpose
Diabetes Mellitus, Type 2
Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
QR-bromocriptine
Sponsored by

About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type 2
Eligibility Criteria
Inclusion Criteria:
- Male and female patients, age 30 to 65 years of age,
- Clinical diagnosis of type 2 diabetes at least 6 months prior to enrollment,
- Stable on current treatment consisting of either human or recombinant multi-dose insulin therapy (MDI) with metformin,
- HbA1c of 7.5-12%, inclusive,
- Demonstrated willingness to check and record blood glucose readings at seven time points as instructed in the study protocol.
- Medically controlled hypertension, at least on one anti-hypertensive
- Medically controlled hyperlipidemia, on or off cholesterol-lowering therapy
- BMI >30
Exclusion Criteria:
- Pregnancy or Lactating,
- Type 1 Diabetes,
- Concomitant use of forbidden medications: prescription sympathomimetics (within seven days of screening), ergot alkaloid derivatives, and anti-migraine medications,
- Patients with history of drug or alcohol abuse within 3 years of enrollment,
Patients at risk for hypotension, including those who have:
- Recent blood donation within 30 days of enrollment,
- A history of syncopal migraines, or
- Significant gastroparesis or orthostatic hypotension which could signify advanced autonomic neuropathy.
- Uncontrolled mental illness especially with history of psychosis,
- Any severe, uncontrolled or terminal medical condition which the investigator feels would interfere with the patient's ability to participate and comply with the study protocol,
- Serum creatinine >1.4mg/dL in females or >1.5mg/dL in males that would preclude the patient from taking metformin,
- LFTs elevated >3x upper limit of normal,
- Patients working rotating, varying or night shifts, or
- Patient with circumstances or abnormalities (e.g. blindness or history of non-compliance) that would interfere with the interpretation of safety or efficacy data or completion of the study.
Sites / Locations
- UT Southwestern Medical Center
- UT Southwestern
Arms of the Study
Arm 1
Arm 2
Arm Type
No Intervention
Experimental
Arm Label
Metformin + Insulin
QR-Bromocriptine +metformin+insulin
Arm Description
5 patients to continue on usual type 2 diabetic treatment consisting of 70/30 insulin, metformin and exercise and nutrition counseling.
study drug add-on the usual therapy
Outcomes
Primary Outcome Measures
Change in A1c
Change from baseline HbA1c between subjects receiving QR-Bromocriptine + metformin + insulin compared to those subjects receiving metformin + insulin
Secondary Outcome Measures
Total Daily Insulin Dose
Change in total daily insulin dose in patients treated with QR-Bromocriptine +metformin +insulin compared to metformin + insulin alone
Full Information
NCT ID
NCT01474018
First Posted
November 2, 2011
Last Updated
September 13, 2019
Sponsor
University of Texas Southwestern Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT01474018
Brief Title
QR-Bromocriptine as an Adjunct to Insulin and Metformin in the Treatment of Type 2 Diabetes
Official Title
QR-Bromocriptine as an Adjunct to Insulin and Metformin in the Treatment of Type 2 Diabetes
Study Type
Interventional
2. Study Status
Record Verification Date
September 2019
Overall Recruitment Status
Completed
Study Start Date
November 2011 (undefined)
Primary Completion Date
May 2012 (Actual)
Study Completion Date
June 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Texas Southwestern Medical Center
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
QR-Bromocriptine as an add-on treatment to insulin and metformin in the management of type 2 diabetes will result in improved glycemic control, reduced exogenous insulin requirement, increased lean fat mass and improved pancreatic beta-cell function.
Detailed Description
To assess improvement in glycemic control, reliance on exogenous insulin, improvements in lean body mass composition, and improvements in pancreatic beta-cell function.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
15 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Metformin + Insulin
Arm Type
No Intervention
Arm Description
5 patients to continue on usual type 2 diabetic treatment consisting of 70/30 insulin, metformin and exercise and nutrition counseling.
Arm Title
QR-Bromocriptine +metformin+insulin
Arm Type
Experimental
Arm Description
study drug add-on the usual therapy
Intervention Type
Drug
Intervention Name(s)
QR-bromocriptine
Other Intervention Name(s)
NDC 6801225820, Cycloset (brand)
Intervention Description
The study drug is added-on to patients on existing type 2 diabetes treatment with insulin +metformin+exercise/nutritional counseling. The study drug is titrated up starting at one 0.8mg tab daily for 1 week, then 2 (0.8mg) tablets for week 2, then 3 tablets for week 3, then 4 tablets for week 4, then 5 tablets for week 5, then six tablets for week 6 (total 4.8). The limiting factor is nausea at which point the patients will back down the highest tolerated dose and continue on that dose for the remainder of the 6 months of the study.
Primary Outcome Measure Information:
Title
Change in A1c
Description
Change from baseline HbA1c between subjects receiving QR-Bromocriptine + metformin + insulin compared to those subjects receiving metformin + insulin
Time Frame
Baseline - 24 weeks
Secondary Outcome Measure Information:
Title
Total Daily Insulin Dose
Description
Change in total daily insulin dose in patients treated with QR-Bromocriptine +metformin +insulin compared to metformin + insulin alone
Time Frame
Baseline - 24 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Male and female patients, age 30 to 65 years of age,
Clinical diagnosis of type 2 diabetes at least 6 months prior to enrollment,
Stable on current treatment consisting of either human or recombinant multi-dose insulin therapy (MDI) with metformin,
HbA1c of 7.5-12%, inclusive,
Demonstrated willingness to check and record blood glucose readings at seven time points as instructed in the study protocol.
Medically controlled hypertension, at least on one anti-hypertensive
Medically controlled hyperlipidemia, on or off cholesterol-lowering therapy
BMI >30
Exclusion Criteria:
Pregnancy or Lactating,
Type 1 Diabetes,
Concomitant use of forbidden medications: prescription sympathomimetics (within seven days of screening), ergot alkaloid derivatives, and anti-migraine medications,
Patients with history of drug or alcohol abuse within 3 years of enrollment,
Patients at risk for hypotension, including those who have:
Recent blood donation within 30 days of enrollment,
A history of syncopal migraines, or
Significant gastroparesis or orthostatic hypotension which could signify advanced autonomic neuropathy.
Uncontrolled mental illness especially with history of psychosis,
Any severe, uncontrolled or terminal medical condition which the investigator feels would interfere with the patient's ability to participate and comply with the study protocol,
Serum creatinine >1.4mg/dL in females or >1.5mg/dL in males that would preclude the patient from taking metformin,
LFTs elevated >3x upper limit of normal,
Patients working rotating, varying or night shifts, or
Patient with circumstances or abnormalities (e.g. blindness or history of non-compliance) that would interfere with the interpretation of safety or efficacy data or completion of the study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Philip Raskin, MD
Organizational Affiliation
UTexas Southwestern
Official's Role
Principal Investigator
Facility Information:
Facility Name
UT Southwestern Medical Center
City
Dallas
State/Province
Texas
ZIP/Postal Code
75390
Country
United States
Facility Name
UT Southwestern
City
Dallas
State/Province
Texas
ZIP/Postal Code
75390
Country
United States
12. IPD Sharing Statement
Learn more about this trial
QR-Bromocriptine as an Adjunct to Insulin and Metformin in the Treatment of Type 2 Diabetes
We'll reach out to this number within 24 hrs